
Curia Announces Expansions to Global Network of Sterile Fill-Finish Sites
Curia, a CDMO, recently shared expansion plans for facilities in Glasgow, UK, and Albuquerque, NM, US.
Curia, a CDMO, recently shared expansion plans for facilities in Glasgow, UK, and Albuquerque, NM, US.
Zofingen, Switzerland-based contract development and manufacturing organization (CDMO) Siegfried has signed a binding agreement to acquire an early-phase CDMO site in Grafton, Wisconsin, US, from Curia. The transaction is expected to close by July 1, subject to customary closing conditions.
US CDMO Curia has begun construction on an expansion of its campus in Albuquerque, New Mexico. The facility designed by Burns & McDonnell will be built by BE&K Building Group.
Research-oriented CDMO Curia, formerly known as AMRI, has agreed to cooperate with Replicate Bioscience, a company searching for ways to prevent drug resistance in cancer and to treat autoimmune and inflammatory disorders and other diseases using self-replicating RNA (srRNA).
US-based CDMO Curia, formerly known as AMRI, has announced that Integrity Bio and LakePharma, companies, both acquired by the company in 2021, have changed their names to Curia to reflect corporate branding.
Curia, the US CDMO formerly known as AMRI, has announced it will invest $35 million to expand commercial manufacturing capacity at its Rensselaer, New York, production facility over the next 18 months.
US CDMO Curia, formerly AMRI, has agreed to acquire LakePharma, a privately held biologics drug discovery, clinical research, development and manufacturing organization. Financial terms of the agreement have not been disclosed.
Only a day after announcing it was changing its name to Curia, the US CDMO known up to now as AMRI announced a “definitive agreement” to acquire Integrity Bio, a privately held biologics formulation and fill & finish organization headquartered in Camarillo, California.